Limonene

Property	Information
Drug Name	Perillyl Alcohol/Limonene
FDA Approval	No (Under investigation for anti-cancer properties)
Used for	Investigational use in recurrent glioma treatment
Clinical Trial Phase	Early-stage clinical trials, including studies in Brazil for recurrent glioma
Clinical Trial Explanation	Not specified
Common Side Effects	Gastro-intestinal side effects when administered orally; intranasal administration used to mitigate this
OS without	Not specified
OS with	Primary GBM: median survival of 5.9 months; Secondary GBM: median survival of 11.2 months
PFS without	Not specified
PFS with	Initial report on recurrent GBM patients showed a PFS-6 value of 48%
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	2
Toxicity Explanation	Perillyl Alcohol and Limonene, despite being under investigation for anti-cancer properties, are derived from citrus oils and generally are not associated with severe toxic effects. They do result in some gastro-intestinal side effects when administered orally, but these side effects are mitigated by intranasal administration. However, as with any treatment, individual responses may vary.

Notes: Perillyl Alcohol and Limonene, derived from citrus oils, have shown potential as anti-cancer agents. Clinical trials have explored their efficacy, particularly through intranasal administration to avoid gastro-intestinal side effects. Early findings suggest a degree of effectiveness in stabilizing disease and extending survival in recurrent GBM patients, with noted variance based on tumor type and location. Further research is needed to fully understand their therapeutic potential and optimal administration method.

From Ben Williams Book: Not specified

Loading comments...